Microsoft Excel LibreOffice Calc

Allergan PLC (NYSE:AGN)

Paying users zone. Data is hidden behind: .

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey
Unlock

This is a one-time payment. There is no automatic renewal.

Income Statement
Quarterly Data

Beginner level

The income statement presents information on the financial results of a company’s business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Allergan PLC, consolidated income statement (quarterly data)

US$ in thousands

Microsoft Excel LibreOffice Calc
3 months ended Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Net revenues
Cost of sales, excludes amortization and impairment of acquired intangibles including product rights
Gross profit
Research and development
Selling and marketing
General and administrative
Amortization
Goodwill impairments
In-process research and development impairments
Asset sales and impairments, net
Operating income (loss)
Interest income
Interest expense
Other income (expense), net
Other income (expense), net
Income (loss) before income taxes and noncontrolling interest
(Provision) benefit for income taxes
Net income (loss) from continuing operations, net of tax
Income (loss) from discontinued operations, net of tax
Net income (loss)
(Income) loss attributable to noncontrolling interest
Net income (loss) attributable to shareholders
Dividends on preferred shares
Net income (loss) attributable to ordinary shareholders

Based on: 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-18), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-08), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-15), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-03), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-09), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-24), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-26), 10-Q (filing date: 2015-11-06), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-11).

Income statement item Description The company
Net revenues Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Allergan PLC’s net revenues increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020.
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Allergan PLC’s operating income (loss) increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020.
Income (loss) before income taxes and noncontrolling interest Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Allergan PLC’s income (loss) before income taxes and noncontrolling interest increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020.
Net income (loss) attributable to shareholders The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Allergan PLC’s net income (loss) attributable to shareholders increased from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.